Increased expression of SOCS3 in monocytes and SOCS1 in lymphocytes correlates with progressive loss of renal function and cardiovascular risk factors in chronic kidney disease

European Journal of Pharmacology

Volumn 593, Issue 1-3, 2008, Pages 99-104

  Rastmanesh, M Mehdi ^a   Bluyssen, Hans A R ^b   Joles, Jaap A ^a   Boer, Peter ^a   Willekes, Nel ^a   Braam, Branko ^a,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ADAM MICKIEWICZ UNIVERSITY   (Poland)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Chronic kidney disease; Inflammation; Peripheral blood mononuclear cell; SOCS

Indexed keywords

INTERLEUKIN 6; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; LYMPHOCYTE; MALE; MONOCYTE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SYSTOLIC BLOOD PRESSURE;

AGED; BIOLOGICAL MARKERS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CYTOKINES; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; LYMPHOCYTES; MALE; MIDDLE AGED; MONOCYTES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 49849099745     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.07.013     Document Type: Article

References (45)

1. Adams T.E., Hansen J.A., Starr R., Nicola N.A., Hilton D.J., and Billestrup N. Growth hormone preferentially induces the rapid, transient expression of SOCS-3, a novel inhibitor of cytokine receptor signaling. J. Biol. Chem. 273 (1998) 1285-1287
2. Alexander W.S., and Hilton D.J. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu. Rev. Immunol. 22 (2004) 503-529
3. Alexander W.S., Starr R., Fenner J.E., Scott C.L., Handman E., Sprigg N.S., Corbin J.E., Cornish A.L., Darwiche R., Owczarek C.M., Kay T.W., Nicola N.A., Hertzog P.J., Metcalf D., and Hilton D.J. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell. 98 (1999) 597-608
4. Ashman N., Macey M.G., Fan S.L., Azam U., and Yaqoob M.M. Increased platelet-monocyte aggregates and cardiovascular disease in end-stage renal failure patients. Nephrol. Dial. Transplant. 18 (2003) 2088-2096
5. Blacher J., Guerin A.P., Pannier B., Marchais S.J., Safar M.E., and London G.M. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 99 (1999) 2434-2439
6. Bolton C.H., Downs L.G., Victory J.G., Dwight J.F., Tomson C.R., Mackness M.I., and Pinkney J.H. Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol. Dial. Transplant. 16 (2001) 1189-1197
7. Briet M., Bozec E., Laurent S., Fassot C., London G.M., Jacquot C., Froissart M., Houillier P., and Boutouyrie P. Arterial stiffness and enlargement in mild-to-moderate chronic kidney disease. Kidney Int. 69 (2006) 350-357
8. Carlos T., Kovach N., Schwartz B., Rosa M., Newman B., Wayner E., Benjamin C., Osborn L., Lobb R., and Harlan J. Human monocytes bind to two cytokine-induced adhesive ligands on cultured human endothelial cells: endothelial-leukocyte adhesion molecule-1 and vascular cell adhesion molecule-1. Blood 77 (1991) 2266-2271
9. Chan C.M. Hyperlipidaemia in chronic kidney disease. Ann. Acad. Med. Singapore. 34 (2005) 31-35
10. Chomarat P., Banchereau J., Davoust J., and Palucka A.K. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat. Immunol. 1 (2000) 510-514
11. Chong M.M., Metcalf D., Jamieson E., Alexander W.S., and Kay T.W. Suppressor of cytokine signaling-1 in T cells and macrophages is critical for preventing lethal inflammation. Blood 106 (2005) 1668-1675
12. Croker B.A., Krebs D.L., Zhang J.G., Wormald S., Willson T.A., Stanley E.G., Robb L., Greenhalgh C.J., Forster I., Clausen B.E., Nicola N.A., Metcalf D., Hilton D.J., Roberts A.W., and Alexander W.S. SOCS3 negatively regulates IL-6 signaling in vivo. Nat. Immunol. 4 (2003) 540-545
13. Egwuagu C.E., Yu C.R., Zhang M., Mahdi R.M., Kim S.J., and Gery I. Suppressors of cytokine signaling proteins are differentially expressed in Th1 and Th2 cells: implications for Th cell lineage commitment and maintenance. J. Immunol. 168 (2002) 3181-3187
14. Farabegoli F., Ceccarelli C., Santini D., and Taffurelli M. Suppressor of cytokine signalling 2 (SOCS-2) expression in breast carcinoma. J. Clin. Pathol. 58 (2005) 1046-1050
15. Flo R.W., Naess A., Lund-Johansen F., Maehle B.O., Sjursen H., Lehmann V., and Solberg C.O. Negative selection of human monocytes using magnetic particles covered by anti-lymphocyte antibodies. J. Immunol. Methods. 137 (1991) 89-94
16. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352 (2005) 1685-1695
17. Herbelin A., Urena P., Nguyen A.T., Zingraff J., and Descamps-Latscha B. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int. 39 (1991) 954-960
18. Herbelin A., Urena P., Nguyen A.T., Zingraff J., and Descamps-Latscha B. Influence of first and long-term dialysis on uraemia-associated increased basal production of interleukin-1 and tumour necrosis factor alpha by circulating monocytes. Nephrol. Dial. Transplant. 6 (1991) 349-357
19. Hernandez-Vargas P., Lopez-Franco O., Sanjuan G., Ruperez M., Ortiz-Munoz G., Suzuki Y., Aguado-Roncero P., Perez-Tejerizo G., Blanco J., Egido J., Ruiz-Ortega M., and Gomez-Guerrero C. Suppressors of cytokine signaling regulate angiotensin II-activated Janus kinase-signal transducers and activators of transcription pathway in renal cells. J. Am. Soc. Nephrol. 16 (2005) 1673-1683
20. Huang K.C., Chen C.W., Chen J.C., and Lin W.W. Statins induce suppressor of cytokine signaling-3 in macrophages. FEBS Lett. 555 (2003) 385-389
21. Ihle J.N. Cytokine receptor signalling. Nature 377 (1995) 591-594
22. Inagaki-Ohara K., Hanada T., and Yoshimura A. Negative regulation of cytokine signaling and inflammatory diseases. Curr. Opin. Pharmacol. 3 (2003) 435-442
23. Krebs D.L., and Hilton D.J. SOCS: physiological suppressors of cytokine signaling. J. Cell Sci. 113 Pt 16 (2000) 2813-2819
24. Leskinen Y., Groundstroem K., Virtanen V., Lehtimaki T., Huhtala H., and Saha H. Risk factors for aortic atherosclerosis determined by transesophageal echocardiography in patients with CRF. Am. J. Kidney Dis. 42 (2003) 277-285
25. Litjens N.H., van Druningen C.J., and Betjes M.G. Progressive loss of renal function is associated with activation and depletion of naive T lymphocytes. Clin. Immunol. 118 (2006) 83-91
26. Marine J.C., McKay C., Wang D., Topham D.J., Parganas E., Nakajima H., Pendeville H., Yasukawa H., Sasaki A., Yoshimura A., and Ihle J.N. SOCS3 is essential in the regulation of fetal liver erythropoiesis. Cell 98 (1999) 617-627
27. Qasimi P., Ming-Lum A., Ghanipour A., Ong C.J., Cox M.E., Ihle J., Cacalano N., Yoshimura A., and Mui A.L. Divergent mechanisms utilized by SOCS3 to mediate interleukin-10 inhibition of tumor necrosis factor alpha and nitric oxide production by macrophages. J. Biol. Chem. 281 (2006) 6316-6324
28. Roberts M.A., Hare D.L., Ratnaike S., and Ierino F.L. Cardiovascular biomarkers in CKD: pathophysiology and implications for clinical management of cardiac disease. Am. J. Kidney Dis. 48 (2006) 341-360
29. Robertson A.K., and Hansson G.K. T cells in atherogenesis: for better or for worse?. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 2421-2432
30. Rostaing L., Borde J.S., Hasle C., Bories P., Allal A., Abbal M., and Durand D. Lack of effect of chronic hepatitis C virus infection on T-cell cytokine production in chronic hemodialysis patients. Am. J. Nephrol. 21 (2001) 194-199
31. Rui L., Yuan M., Frantz D., Shoelson S., and White M.F. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J. Biol. Chem. 277 (2002) 42394-42398
32. Sasaki A., Yasukawa H., Shouda T., Kitamura T., Dikic I., and Yoshimura A. CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. J. Biol. Chem. 275 (2000) 29338-29347
33. Schumacher H.R., Garvin D.F., and Triplett D.A. Introduction to laboratory hematology and hematopathology. first ed. (1984), Alan R. Liss. Inc., New York, NY 9-107
34. Sester U., Sester M., Hauk M., Kaul H., Kohler H., and Girndt M. T-cell activation follows Th1 rather than Th2 pattern in haemodialysis patients. Nephrol. Dial. Transplant. 15 (2000) 1217-1223
35. Starr R., Willson T.A., Viney E.M., Murray L.J., Rayner J.R., Jenkins B.J., Gonda T.J., Alexander W.S., Metcalf D., Nicola N.A., and Hilton D.J. A family of cytokine-inducible inhibitors of signalling. Nature 387 (1997) 917-921
36. Starr R., Metcalf D., Elefanty A.G., Brysha M., Willson T.A., Nicola N.A., Hilton D.J., and Alexander W.S. Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1. Proc. Natl. Acad. Sci. U S A. 95 (1998) 14395-14399
37. Stenvinkel P., Ketteler M., Johnson R.J., Lindholm B., Pecoits-Filho R., Riella M., Heimburger O., Cederholm T., and Girndt M. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia-the good, the bad, and the ugly. Kidney Int. 67 (2005) 1216-1233
38. Tan J.C., and Rabkin R. Suppressors of cytokine signaling in health and disease. Pediatr. Nephrol. 20 (2005) 567-575
39. Tang J., and Raines E.W. Are suppressors of cytokine signaling proteins recently identified in atherosclerosis possible therapeutic targets?. Trends Cardiovasc. Med. 15 (2005) 243-249
40. Tang J., Kozaki K., Farr A.G., Martin P.J., Lindahl P., Betsholtz C., and Raines E.W. The absence of platelet-derived growth factor-B in circulating cells promotes immune and inflammatory responses in atherosclerosis-prone ApoE-/- mice. Am. J. Pathol. 167 (2005) 901-912
41. Tsirpanlis G. Is inflammation the link between atherosclerosis and vascular calcification in chronic kidney disease?. Blood Purif. 25 (2007) 179-182
42. Vuurmans T.J., Boer P., and Koomans H.A. Effects of endothelin-1 and endothelin-1 receptor blockade on cardiac output, aortic pressure, and pulse wave velocity in humans. Hypertension 41 (2003) 1253-1258
43. Wong P.K., Egan P.J., Croker B.A., O'Donnell K., Sims N.A., Drake S., Kiu H., McManus E.J., Alexander W.S., Roberts A.W., and Wicks I.P. SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis. J. Clin. Invest. 116 (2006) 1571-1581
44. Yamamoto T., Y.H., Koga M., et al. Lacking the SOCS3 gene in macrophages prevents the development of atherosclerosis in ApoE deficient mice. Circ. J. 71 (2007) 170
45. Yoshimura A., Nishinakamura H., Matsumura Y., and Hanada T. Negative regulation of cytokine signaling and immune responses by SOCS proteins. Arthritis Res. Ther. 7 (2005) 100-110